Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02284906




Registration number
NCT02284906
Ethics application status
Date submitted
4/11/2014
Date registered
6/11/2014
Date last updated
2/07/2019

Titles & IDs
Public title
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
Scientific title
A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease
Secondary ID [1] 0 0
U1111-1154-9637
Secondary ID [2] 0 0
AD-4833/TOMM40_303
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Mild Cognitive Impairment Due to Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias
Mental Health 0 0 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pioglitazone
Treatment: Drugs - Placebo

Experimental: Pioglitazone 0.8 mg - Pioglitazone 0.8 mg, tablets, orally, once, daily, for minimum of 2 years.

Placebo Comparator: Placebo - Pioglitazone placebo-matching tablets, orally, once, daily, for minimum of 2 years.


Treatment: Drugs: Pioglitazone
Pioglitazone tablets

Treatment: Drugs: Placebo
Pioglitazone placebo-matching tablets
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Extension Study Baseline in Composite Score of a Broad Cognitive Test Battery at Month 24
Timepoint [1] 0 0
Baseline and Month 24
Secondary outcome [1] 0 0
Time to Diagnosis of Alzheimer's Disease (AD) Dementia
Timepoint [1] 0 0
Day 1 and every 6 months (up to maximum of 36 months)

Eligibility
Key inclusion criteria
1. Completed the pivotal AD-4833/TOMM40_301 study with an adjudicated diagnosis of mild
cognitive impairment (MCI) due to Alzheimer's Disease (AD) without ongoing serious
adverse events (SAEs) from AD-4833/TOMM40_301.

2. Is male or female and is at least 65 years of age at the time of the Baseline Visit.

3. In the opinion of the investigator, is capable of understanding and complying with the
protocol requirements.

4. The participant or, when applicable, the participant's legally acceptable
representative signs and dates a written, informed consent form and any required
privacy authorization prior to the initiation of any study procedures.

5. Must be living independently or in nonmedical residential care.

6. Has a project partner able to separately consent on his/her own behalf and take part
in the study (with the intent to do so as long as the participant is enrolled),
providing information on the cognitive, functional, and behavioral status of the
participant and assisting with observation of adverse events (AEs) and monitoring of
study medication, if needed. Project partners participating in the pivotal
AD-4833/TOMM40_301 study are encouraged to participate in this extension study in this
capacity.
Minimum age
65 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Completed the pivotal AD-4833/TOMM40_301 study with an adjudicated diagnosis of AD
dementia.

2. Has a current diagnosis of significant psychiatric illness, per Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition (including but not limited to
major depressive disorder, anxiety disorders) and is in an acute phase/episode, or the
participant has a current diagnosis or history of schizophrenia or bipolar disorder.

3. Has a glycosylated hemoglobin (HbA1c) >8% at the extension study Baseline Visit or
requires treatment with insulin, triple oral antidiabetic therapy or a peroxisome
proliferator-activated receptor gamma (PPAR-?) agonist.

4. Has a clinically significant unstable illness, for example, hepatic impairment or
renal insufficiency, or cardiovascular, pulmonary, gastrointestinal (including s/p
gastric bypass surgery), endocrine, neurological, rheumatologic, immunologic,
infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.

5. Is an immediate family member, study site employee, or is in a dependent relationship
with a study site employee who is involved in conduct of this study (eg, spouse,
pivotal, child, sibling) or may consent under duress.

6. Is required to take excluded medications.

7. Has a history of hypersensitivity or allergies to pioglitazone or related compounds.

8. Had any of the following values at the extension study Baseline Visit:

1. A serum total bilirubin value >15 x upper limit of normal (ULN).

2. A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value
>2 x ULN.

3. Unexplained microscopic/macroscopic hematuria on 2 repeat examinations within 2
weeks.

9. Has a disease or takes medication that, in the opinion of the investigator, could
interfere with the assessments of safety, tolerability, or efficacy, or prevent the
participant from adequately participating in the study or continue for the anticipated
duration of the study.

10. Has received any investigational compound, with the exception of treatment during the
AD-4833/TOMM40_301 study, within 30 days prior to Baseline or 5 half-lives prior to
Baseline or is currently participating in another study that entails the
administration of an investigational or marketed drug, supplement, or intervention
including, but not limited to diet, exercise, lifestyle, or invasive procedure.

11. Has any cancer that has been in remission for less than 2 years from the extension
study Baseline Visit. Participants with basal cell or stage I squamous cell carcinoma
of the skin will be eligible. Participants with current diagnosis of bladder cancer
are not eligible irrespective of the remission status.

12. Has a current diagnosis of macular edema, degeneration or any maculopathy.

13. Has a history or current diagnosis of congestive heart failure (CHF), New York Heart
Association class III-IV.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/02/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
8/05/2018
Sample size
Target
Accrual to date
Final
40
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
- North Ryde
Recruitment hospital [2] 0 0
- Southport
Recruitment hospital [3] 0 0
- Heidelberg West
Recruitment hospital [4] 0 0
- Nedlands
Recruitment postcode(s) [1] 0 0
2113 - North Ryde
Recruitment postcode(s) [2] 0 0
4215 - Southport
Recruitment postcode(s) [3] 0 0
3081 - Heidelberg West
Recruitment postcode(s) [4] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Iowa
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
Nevada
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Utah
Country [16] 0 0
United States of America
State/province [16] 0 0
Wisconsin
Country [17] 0 0
Switzerland
State/province [17] 0 0
Basel
Country [18] 0 0
United Kingdom
State/province [18] 0 0
Avon
Country [19] 0 0
United Kingdom
State/province [19] 0 0
Devon
Country [20] 0 0
United Kingdom
State/province [20] 0 0
Greater London
Country [21] 0 0
United Kingdom
State/province [21] 0 0
Greater Manchester
Country [22] 0 0
United Kingdom
State/province [22] 0 0
Lancashire
Country [23] 0 0
United Kingdom
State/province [23] 0 0
Middlesex
Country [24] 0 0
United Kingdom
State/province [24] 0 0
Strathclyde
Country [25] 0 0
United Kingdom
State/province [25] 0 0
Tayside Region

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Takeda
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the effect of pioglitazone at 24 months compared
with placebo on cognitive decline in high-risk participants who have completed the
AD-4833/TOMM40_301 study [NCT01931566] with an adjudicated diagnosis of mild cognitive
impairment (MCI) due to Alzheimer's Disease (AD).
Trial website
https://clinicaltrials.gov/ct2/show/NCT02284906
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director Clinical Science
Address 0 0
Takeda
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02284906